Global /China /Industrials /Specialty Business Services /2185

Shanghai Bio-heart Biological Technology Co., Ltd.

2185

• SHEK: 2185 • Delayed

4.03HKD 0.5%

0.5143 USD

As of 15 June 2026, Shanghai Bio-heart Biological Technology Co., Ltd. has a market cap of $124.57M USD, ranking #24050 globally and #5864 in China. It ranks #5545 in the Industrials sector, and #611 in the Specialty Business Services industry.

Global Rank

24050

Country Rank

5864

Sector Rank

5545

Industry Rank

611

Key Stats

Market Cap

$124.57MUSD

976.1M HKD

Enterprise Value

$116.26MUSD

910.99M HKD

Revenue (TTM)

$6.38MUSD

50.0M HKD

EBITDA (TTM)

-$9.22MUSD

-72.22M HKD

Net Income (TTM)

-$9.95MUSD

-77.96M HKD

EBITDA Margin

-144%

Profit Margin

-156%

PS Ratio

19.5

PB Ratio

1.4

Company Profile

Country (HQ)

China

Sector

Industrials

Industry

Specialty Business Services

CEO

Li Wang open_in_new

Employees

Founded

2014

Website

bio-heart.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0.5%	-5%	1.8%	-27%	-50%	-30%	64%	-38%	-86%

News

Markets

Exchange	Ticker	Price	Quotes
Hong Kong Stock Exchange (SHEK / HKEX) MIC: XHKG PRIMARY	2185 上海百心安生物技术股份有限公司 Class H ISIN: CNE100004JH3 Shares Out.: Shares Outstanding: 235.703M¹ Shares Float: 105.874M² TV: TradingView: HKEX: 2185 SA: Stock Analysis: HKG: 2185 YF: Yahoo Finance: 2185.HK GF: Google Finance: HKG: 2185 BA: Barron's: 2185 MS: Morningstar: XHKG: 02185	4.03 HKD	TV: TradingView: HKEX: 2185 SA: Stock Analysis: HKG: 2185 YF: Yahoo Finance: 2185.HK GF: Google Finance: HKG: 2185 BA: Barron's: 2185 MS: Morningstar: XHKG: 02185

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Shanghai Bio-heart Biological Technology Co., Ltd.

Shanghai Bio-heart Biological Technology Co., Ltd. an interventional cardiovascular device company, engages in the research and development of therapies for unmet medical needs of patients in the People’s Republic of China. The company develops Bioheart, a bioresorbable scaffolds (BRS) system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a renal denervation (RDN) product candidate for the treatment of uncontrolled hypertension and resistant hypertension; and drug coated balloon (DCB), a sirolimus drug-eluting balloon catheter designed for instent restenosis. Shanghai Bio-heart Biological Technology Co., Ltd. was founded in 2014 and is headquartered in Shanghai, the People’s Republic of China.

Similar Companies

Industry: Specialty Business Services (China)

Name	Market Cap (USD) diff.	PE	Country
WuXi XDC Cayman Inc. SHEK: 2268	$9.42B 73.79B HKD 7K%	47.0	China
Beijing Compass Technology Development Co., Ltd. SHE: 300803	$8.77B 59.36B CNY 7K%	296.1	China
TAL Education Group NYSE: TAL	$6.6B 5K%	11.8	China
Hui Lyu Ecological Technology Groups Co.,Ltd. SHE: 001267	$6.26B 42.34B CNY 5K%	480.6	China
Jiangsu Boqian New Materials Stock Co., Ltd. SSE: 605376	$4.62B 31.29B CNY 4K%	128.4	China
Suzhou Tianmai Thermal Technology Co., Ltd. SHE: 301626	$4.6B 31.16B CNY 4K%	163.3	China

Industry: Specialty Business Services (Global)

Name	Market Cap (USD) diff.	PE	Country
Shopify Inc. NASDAQ: SHOP	$158.14B 127K%	129.8	Canada
Verisure plc STO: VSURE	$132.81B 114.8B EUR 107K%	-	United Kingdom
Cintas Corp. NASDAQ: CTAS	$69.6B 56K%	36.8	United States
RELX PLC LSE: REL	$63.62B 47.6B GBP 51K%	23.9	United Kingdom
PayPal Holdings, Inc. NASDAQ: PYPL	$45.83B 37K%	9.4	United States
T Thomson Reuters Corp. NEO: TRI	$41.8B 56.91B CAD 33K%	-	Canada

chevron_leftBack